I. E. Kaukhova

I. E. Kaukhova

Auto-generated profile, based on publicly available information

I. E. Kaukhova

Санкт-Петербургский химико-фармацевтический университет

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Actual Problems of Theoretical and Clinical Medicine
Verified
Journal Article
Open access
PDF file
SIS. M. Imanalieva
S. M. Imanalieva
BSB. A. Sagyndykova
B. A. Sagyndykova
IKI. E. Kaukhova
I. E. Kaukhova
MAMurat Ashirov
Murat Ashirov
GSG. B. Shoinbayeva
G. B. Shoinbayeva
The development of safe and effective anti-inflammatory dosage forms for children is one of the most important areas of modern pharmaceutical science. Among nonsteroidal anti-inflammatory drugs, meloxicam is among the most commonly used substances in clinical practice. Objective. To study the preclinical toxicity and anti-inflammatory activity of meloxicam tablets for children (coated, prolonged effects, special dose). Methods and materials: acute toxicity in animals was determined, as well as an assessment of specific pharmacological activity in models of histamine-induced and carrageenan aseptic inflammation. Study results: The study showed that Meloxicam tablets for children are non-toxic and have greater anti-inflammatory activity than the comparison drug. The study on the specific activity of Meloxicam 3.75 mg tablets for children + cyanocobalamin 0.002 mg demonstrated their high anti-inflammatory activity in experimental aseptic inflammation models. This indicates an increased anti-inflammatory effect of meloxicam when combined with cyanocobalamin. Conclusion: the results showed that the anti–inflammatory activity of the studied drug, meloxicam children’s tablets, is higher than that of the comparative drug meloxicam.